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Abstract
IMPORTANCE This is the first cost-effectiveness analysis of a brief therapy, the Attempted Suicide
Short Intervention Program (ASSIP), for individuals who attempt suicide.
OBJECTIVE To explore the cost-effectiveness of the ASSIP intervention in the context of the Swiss
health care system.
DESIGN, SETTING, ANDPARTICIPANTS In this economic evaluation, the cost-effectiveness
analysis was performed from a health care perspective between January 2017 and April 2018 using
data from a randomized clinical trial conducted between June 2009 and December 2014.
Participants were individuals who had attempted suicide and were receiving treatment at a
psychiatric university hospital in Switzerland that provides inpatient and outpatient services for
suicide attempters referred from an emergency department of a general hospital.
INTERVENTIONS The intervention group received 3manual-based therapy sessions followed by
regular personalized letters over 24 months. The control group was offered a single suicide risk
assessment.
MAINOUTCOMES ANDMEASURES Themain economic analysis explored cost per suicide attempt
avoided expressed in 2015 Swiss francs (CHF). Cost-effectiveness planes were plotted and cost-
effectiveness acceptability curves calculated.
RESULTS One hundred twenty participants (mean [SD] age, 37.8 [14.4] years; 66 [55%] women and
54 [45%]men)were assigned to an intervention group or a control group, eachwith 60 participants.
At 24months of follow-up, 5 suicide attempts were reported in the ASSIP group among 59
participants with follow-up data available, and 41 were reported in the control group among 53
participants with follow-up data available. The ASSIP group had higher intervention costs, with CHF
1323 vs CHF 441 for the control group. At 24 months of follow-up, psychiatric hospital costs were
lower in the ASSIP group than in the control group, although this differencewas not significant (mean
[SD], CHF 20 559 [38 676] vs CHF 45 488 [73 306]; mean difference, CHF −16081; 95% CI, CHF
−34 717 to 1536; P = .11). General hospital costs were significantly lower for the ASSIP group. Total
health care costs were also lower, but the difference was not significant (mean [SD], CHF 21 302
[38 819] vs 41 287 [74 310]; difference, CHF −12 604; 95% CI, CHF −29837 to 625; P = .14). In a base-
case analysis, ASSIP was dominant, with significantly fewer reattempts at lower overall cost. The
intervention had a 96% chance of being less costly andmore effective. A sensitivity analysis showed
(continued)
Key Points
Question Is the Attempted Suicide
Short Intervention Program, a brief
novel therapy for individuals who
attempt suicide, cost-effective
compared with a suicide risk
assessment?
Findings In this economic evaluation
conducted alongside a randomized
clinical trial that included 120 Swiss
adults, the intervention group had
significantly lower levels of suicide
reattempts compared with the control
group at lower health care costs, with a
96% chance of being less costly and
more effective in a sensitivity analysis.
Meaning In the context of the Swiss
health care system, the Attempted
Suicide Short Intervention Programwas
found to be cost saving as a follow-up
treatment for attempted suicide.
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Abstract (continued)
a 96% and 95% chance of ASSIP beingmore effective and less costly at willingness-to-pay levels of
CHF 0 and CHF 30000, respectively.
CONCLUSIONS ANDRELEVANCE The ASSIP intervention is a cost-saving treatment for individuals
who attempt suicide. The findings support the use of ASSIP as a treatment for suicide attempters.
Further studies are needed to determine cost-effectiveness in other contexts.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02505373.
JAMA Network Open. 2018;1(6):e183680. doi:10.1001/jamanetworkopen.2018.3680
Introduction
According toWorld Health Organization statistics, more than 800000 people die of suicide every
year, and 10 to 20 timesmore people attempt suicide.1 Attempted suicide is one of themost frequent
reasons for emergency hospital admissions.2 In the United States, it is estimated that each year 1.4
million people attempt suicide.3 Between 14% and 22% of these individuals will have repeat suicide
attempts within a year.4 Furthermore, people with a history of attempted suicide have up to 100
times increased risk of completed suicide compared with the general population.5
The economic costs associated with health and social care services due to suicidal behaviors,
such as medical emergency treatment, general and psychiatric hospitalizations, outpatient care,
informal care costs, and productivity losses, are enormous. For example, in the United States, the
yearly costs of suicidal behavior, which includes suicide and attempted suicide, have been estimated
at $93.5 billion.6 In Scotland, the costs of all suicides per year have been reported to be over £1
billion.7 For attempted suicide, the mean costs at a hospital in Oxford in the United Kingdom,
including psychosocial assessment and general hospital services, were estimated to be £809 per
patient. The extrapolated costs for England were £162million per year.8 In Switzerland, the total
medical and psychiatric treatment costs of suicide attempts for a population of 8million people were
estimated at CHF 191 million per year.9
The evidence that specific treatments are effective in reducing the risk of repeated attempts so
far is limited.10-13 Economic evaluations of effective interventions to prevent suicidal behaviors
are scarce.14
The ASSIP intervention is a novel therapy for people who attempt suicide. It is brief, highly
structured, and relatively easy to learn and to implement. In a randomized clinical trial (RCT) with a
24-month follow-up, ASSIP was associated with an 80% reduction in the risk that patients would
reattempt suicide.15 As part of this trial, an economic evaluation was conducted post hoc to explore
the cost-effectiveness of ASSIP to inform health system resource allocation decisions.
Methods
Trial Design and Participants
Patients who had attempted suicide and who had presented to the emergency department at the
general hospital at the University of Bern in Switzerland were recruited from inpatient or outpatient
follow-up treatment and were randomly assigned to either the ASSIP or control groups from June
2009 until December 2012 with a 2-year follow-up ending in December 2014. This economic
evaluation is reported here as recommended in the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) reporting guideline.16 The trial protocol is available in Supplement 1.
The cost-effectiveness analysis was subsequently conducted between January 2017 and April 2018.
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The term attempted suicide used in the study followed the definition by Silverman et al as a “self-
inflicted, potentially injurious behavior with a nonfatal outcome for which there is evidence (either
explicit or implicit) of intent to die.”17
Randomization andMasking
Patients who gave informed consent were randomly assigned using shuffled unmarked sealed
envelopes between groups. Suicidality was assessed with the Suicide Status Form and individuals
were diagnosed using the International Classification of Diseases, Tenth Revision.18 The study was
approved by the local research ethics committee of the University of Bern in accordance with the
Declaration of Helsinki.19
Interventions
The ASSIP intervention consisted of three 60-minute face-to-face sessions, followed by
semistructured personalized letters sent to individuals 6 times over 24months.20 The conceptual
model for the intervention considers suicidal behavior as a goal-oriented action rather than a form
of illness.
The ASSIP protocol is described in detail in themanual.20 In the first session, the therapist
focuses on the patient’s narrative of the background of the suicidal crisis and establishes a
collaborative working alliance. In a video-playback session, patient and therapist collaboratively
review the recorded interview. A psychoeducational text with the title “Suicide Is Not a Rational Act”
is handed out to the patient. In the third session, a case conceptualization is collaboratively
formulated, identifying the patient’s personal vulnerability and suicide trigger, warning signs, and
safety strategies tailored to individual needs. Patients are reminded of their own personal safety
strategies with a credit-card-sized summary listing emergency contact details. In the control group
of the RCT, individuals received 1 single session for suicide risk assessment, which was sent to the
patient’s physician.
Clinical Outcomes
Outcomes weremeasured at 6, 12, 18, and 24months after the intervention. The primary outcome
measure was the total number of suicide attempts in both groups. For further details, see the original
publication.15
Resource Use and Costs
The economic evaluation was performed from a health care system perspective. In Switzerland this
is of interest not only to hospitals, but also to insurance providers and the cantonal (regional) health
authorities who are the major funders of health care services. Resource use data on the number of
inpatient days and the number of outpatient sessions attended were collected from patient self-
reports every 6 months. Costs of resources used were estimated by applying relevant unit costs in
Swiss Francs (CHF) for the financial year 2015. General hospital emergency department
hospitalizations related to suicidal behaviors were estimated retrospectively by examining patient
hospital records. Training costs were added in a sensitivity analysis to explore the implications for
future implementation costs. This seemed relevant because the 2 health care professionals providing
ASSIP in this study did not need training as developers of the treatment protocol. Unit costs and
training costs obtained from university hospital staff are presented in eTable 1 and eTable 2 in
Supplement 2. Alternative scenarios explored whether results were robust by excluding intervention
costs, using undiscounted costs and effects, and including imputed values.
Statistical Analysis
The ASSIP trial was powered using the results of previous trials.15 Economic analyses were performed
based on amodified intention-to-treat principle21 by including all study participants who had any
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data for at least 1 follow-up point available during the entire 24months in the group to which they
had initially been randomized in themain analysis.
Costs were compared at each point over the entire 24-month period. They are reported as
mean values with standard deviations. Baseline costs included costs for previous suicide attempts
related to days in the hospital as well as outpatient costs incurred in the 6months prior to
intervention. It seemed important to adjust mean costs for these baseline costs due to a significant
difference reported in the original study,15 especially in outpatient sessions. Mean differences and
95% confidence intervals were obtained by bias-corrected and accelerated nonparametric bootstrap
regressions22 using 1000 replications that included baseline costs as a covariate.
In our study, cost-effectiveness was explored as the incremental cost to prevent 1 additional
attempted suicide using the net-benefit approach.23 In the base case analysis, costs and effects
beyond 12 months were discounted at 3.5% and 1.5%, respectively, as the intervention lasted over
1 year.24
Although there is no officially recommended discount rate in Switzerland at a national level,
discounting rates in health economic evaluations by convention generally range from 1.5% to 5% to
reflect the time preference correctly.25 It is commonly recommended to use lower discounting rates
for the effectiveness of public health interventions aswell as preventive interventions such as suicide
or attempted suicide prevention strategies.26 This is because the benefits from a preventive
intervention are more likely to be realized over a longer time horizon. If the same discount rates are
used for both costs and effects, the potential benefits, which would be realized in the longer term,
can be undervalued. Therefore, to prevent this and reflect reality, we applied the lower discount rate
of 1.5% for effects and 3.5% for costs, as recommended by theNational Institute for Health and Care
Excellence in the United Kingdom.26 In addition, we varied discount rates from 0% (undiscounted)
to 6% for both costs and effects to test the sensitivity of the results by using higher discount rates as
a conservative estimate.
A joint distribution of incremental mean costs and effects between the 2 groups was generated
using nonparametric bootstrapping. These data were used to explore the probability that the
intervention is the optimal choice, subject to a range of possible threshold values that a decision
makermight bewilling to pay for an improvement in our outcome of interest in a Swiss context. Cost-
effectiveness acceptability curves were generated by plotting these probabilities for a range of
plausible threshold values. Missing costs and outcomes were imputed usingmultiple imputation
chained equations with predictive meanmatching to deal with skewness. All analyses were 2-tailed
and a P value of less than .05 was considered significant. The data were analyzed using SPSS
statistical software version 21 (IBM) and STATA statistical software version 15 (StataCorp).
Results
Effectiveness
One hundred twenty participants (mean [SD] age, 37.8 [14.4] years; 66 [55%] women and 54 [45%]
men) were included in the study with 60 in each group. No significant differences were found in
study participants’ characteristics between the 2 groups, except in the number of outpatient visits
before the suicide attempt (median [IQR] number of visits, 8 [2.25-15.75] in the intervention vs 2.5
[0-10.5] in the control group).25 The CONSORT diagram for the trial and baseline characteristics of
the participants are available in the previously published article.15
At 24months of follow-up, 5 suicide attempts were recorded of 59 participants in the ASSIP
group for whom follow-up data were available, compared with 41 attempts of 53 participants in the
control group. The mean (SD) number of suicide attempts per person at 2 years of follow-up was
0.084 (0.278) in the ASSIP group and 0.769 (1.833) in the control group (incremental mean [SE]
difference, −0.685 [0.263]; 95% CI, −1.201 to −0.169; P = .009).
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Intervention Costs
Three sessions were provided in the ASSIP group and 1 session in the control group. Sessions
normally consisted of 60minutes face to face with patients plus 30minutes for record keeping and
administrative work. Attendance rates were 100% in each group. The mix of staff time to deliver the
interventions to service users was approximately 40% by a psychiatrist and 60% by a clinical
psychologist. The ASSIP group had higher intervention costs, with CHF 1323 vs CHF 441 for the
control group. Because of the different number of sessions provided, the intervention costs were 3
times higher in the ASSIP group compared with the control group.
Resource Use for Psychiatric Care Services
There were 1176 and 2915 psychiatric inpatient days in total in the ASSIP group and the control group,
respectively, and 2041 and 1638 outpatient sessions in the 2 groups, respectively. On average,
patients in the ASSIP group had fewer days of inpatient care than the control group (mean [SD], 21
[57] days vs 60 [111] days). On the other hand, ASSIP participants had a slightly higher mean number
of outpatient sessions comparedwith patients in the control group (mean [SD], 36 [44] sessions vs
33 [44] sessions). This suggests a shift of costs frommore expensive forms of inpatient care to less
costly outpatient care.
Health Service Costs
Mean costs for inpatient care services in the psychiatric hospital, measured every 6months, were
higher for people in the control group than those in the ASSIP group, although there was no clear
pattern in outpatient costs between the 2 groups. However, no significant differences in psychiatric
hospital costs were found when we looked at the group difference in psychiatric service costs as
snapshots at different time points, as shown in Table 1.
From a health care payer perspective, psychiatric hospital costs, including inpatient and
outpatient care costs, were lower in the intervention group compared with the control group. This
difference was not significant (mean [SD], CHF 20 559 [38 676] vs CHF 45 488 [73 306]; adjusted
mean difference, CHF −16081; 95% CI, CHF −34 717 to 1536; P = .11). General hospital costs were
significantly lower in the intervention group than the control group (mean [SD], CHF 456 [1511] vs
CHF 4186 [9966]; adjustedmean difference, CHF −3045; 95%CI, −6333 to −1128; P = .005). General
hospital costs included assessment, consultation, and liaison psychiatric services. Overall, total
health care costs were lower in the ASSIP group than the control group. This difference was not
significant (mean [SD], CHF 21 302 [38 819] vs CHF 41 287 [74 310]; difference, CHF −12 604; 95%CI,
CHF −29837 to 625; P = .14), as shown in Table 2.
Table 1. Mean Psychiatric Health Care Costs for Every 6-Month Period at 6, 12, 18, and 24Months
Types of Costs and Time Points
Mean (SD)
Unadjusted Cost
Difference, Mean
Adjusted Cost
Difference, Mean (95% CI) P ValueASSIP Cost, CHF Control Cost, CHF
Inpatient Care
Baseline (n = 57 vs 59) 62 248 (156 605) 69 871 (161 211) −7623 −7622 (−60 963 to 47 570) .81
0-6 mo (n = 42 vs 42) 9743 (19 636) 22 267 (35 977) −12 524 −9805 (−21 553 to 677) .11
6-12 mo (n = 37 vs 36) 4031 (17 326) 12 137 (26 444) −8106 −6037 (−14 427 to 844) .24
12-18 mo (n = 36 vs 33) 4092 (14 325) 5816 (18 685) −1724 −1725 (−9984 to 5416) .69
18-24 mo (n = 54 vs 38) 1169 (4097) 8978 (29 664) −7809 −7809 (−19 181 to 814) .19
Outpatient Care
Baseline (n = 58 vs 60) 2176 (2338) 1556 (2622) 620 620 (−247 to 1444) .17
0-6 mo (n = 43 vs 42) 3676 (3700) 2514 (3163) 1162 672 (−512 to 1831) .29
6-12 mo (n = 37 vs 36) 2133 (2612) 2493 (4076) −360 −647 (−2418 to 499) .52
12-18 mo (n = 36 vs 35) 2258 (3165) 1576 (2331) 682 682 (−540 to 1946) .31
18-24 mo (n = 54 vs 38) 1570 (2150) 1925 (3344) −355 −355 (−1716 to 838) .58
Abbreviations: ASSIP, Attempted Suicide Short Intervention Program; CHF, Swiss francs.
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Regarding the incremental cost-effectiveness ratio, the intervention group had both amuch
lower level of recurring attempted suicides (mean [SD] attempts per person, 0.084 [0.278] vs 0.769
[1.833]; mean difference, −0.685; 95% CI, −1.201 to −0.169; P = .009) and lower costs (mean [SD]
costs per person, CHF 21 302 [38 819] vs CHF 41 287 [74 310]; mean difference, −12 604; 95% CI,
−29 837 to 625; P = .14) than the control group. In this case, ASSIP is considered by health economists
to be the dominant intervention. The intervention had a 96% chance of being less costly andmore
effective. By convention, the incremental cost-effectiveness ratio value is not reported. The analysis
strongly suggests that ASSIP would be a cost-saving strategy.
In a series of sensitivity analyses, we explored the impacts of varying assumptions by decreasing
costs (ie, excluding intervention costs from total costs in themain analysis) and by increasing costs
(ie, adding training costs) to see whether changes in cost components would make any difference to
the final conclusions. In addition, discount rates were varied between 0% (undiscounted) to the
most conservative estimates of 6% for both costs and outcomes. Sensitivity analyses had no impact
on the interpretation of the findings, consistently showing lower costs in the ASSIP group than in the
control group. Table 3 shows that these differences in costs were not significant.
This is also confirmed in the cost-effectiveness plane shown in Figure 1. In the scatterplot, the
majority of bootstrapped paired dots representing differences in pairs of costs and effects were
scattered across the southwest quadrant. This indicates that the ASSIP intervention is highly likely to
be less costly andmore effective in reducing the number of reattempts compared with the control
group (negative incremental effect is desirable, as this means reduced attempted suicides).
In Figure 2, the cost-effectiveness acceptability curve shows that ASSIP would potentially be
cost saving even at the lower ranges of willingness to pay. There is a 96% chance of ASSIP being less
costly andmore effective if willingness-to-pay is CHF0 and a 95% chance at CHF 30000. Therefore,
it can be concluded that the sensitivity analyses show highly stable results and that ASSIP is a
worthwhile investment.
Discussion
The probability that ASSIP was cost saving at 24months was very high even at very low levels of
willingness to pay. Most of the cost savings were driven by significantly lower costs for general
hospital services and less use of inpatient care services in the ASSIP group. Perhaps the absence of a
Table 2. Mean Total Costs Per Participant Over 24-Month Follow-Up
Cost Type
Mean (SD)
Unadjusted Mean
Cost Difference
Adjusted Mean
Cost Difference (95% CI) P ValueASSIP Cost, CHF Control Cost, CHF
Intervention (n = 60 vs 60) 1323 (0) 441 (0) 882 882 (882 to 882) .002
Psychiatric hospital (n = 54 vs 42) 20 559 (38 676) 45 488 (73 306) −24 929 −16 081 (−34 717 to 1536) .11
General hospital (n = 59 vs 53) 456 (1511) 4186 (9966) −3730 −3045 (−6333 to −1128) .005
Total costs including intervention costs
(n = 60 vs 60)
21 302 (38 819) 41 287 (74 310) −19 985 −12 604 (−29 837 to 625) .14
Abbreviations: ASSIP, Attempted Suicide Short Intervention Program; CHF, Swiss francs.
Table 3. Sensitivity Analyses for 24-Month Costs Per Person
Assumptions and Cost Scenarios
Mean (SD)
Unadjusted Mean
Difference
Adjusted Mean
Difference (95% CI) P ValueASSIP Cost, CHF Control Cost, CHF
Excluding intervention costs 20 318 (39 063) 46 240 (77 531) −25 922 −17 031 (−35 014 to 952) .06
Including training costs 21 515 (38 819) 41 287 (74 310) −19 772 −12 451 (−29 875 to 1617) .16
Undiscounted costs 21 531 (39 257) 41 725 (75 368) −20 194 −12 737 (−29 291 to 1427) .14
Imputed costs 21 302 (38 819) 41 287 (74 310) −19 985 −13 851 (−30 681 to 2979) .11
Costs discounted at 6% 21 148 (38 526) 40 991 (73 601) −19 843 −12 615 (−31 842 to 1597) .17
Abbreviations: ASSIP, Attempted Suicide Short Intervention Program; CHF, Swiss francs.
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significant difference in psychiatric health service costs, despite the consistently lower inpatient
costs in the intervention group over time, could be attributed to the lack of power to detect
significant differences at each time point due to the small sample size. In theory, it is also partly
because larger sample sizes are generally required to detect a significant difference in costs than in
effects, although in reality, power calculations for RCTs are usually based on primary clinical
outcomes rather than costs.23 Therefore, more studies with larger sample sizes might be helpful to
confirm the significant difference in costs in future RCTs. However, this is indeed an ethical dilemma
in RCTs with suicidal patients. To replicate an RCT using ASSIP in different health care systems, the
control conditionmust always include an adequate treatment as usual, which includes the possibility
of emergency contacts during follow-up.
Establishing the cost-effectiveness of new treatments should have a high priority, given the
number of suicide attempts and the burden on health care systems.2 For instance, only half of
individuals who attempt suicide and are discharged from emergency departments received
follow-up outpatient care for their mental health within 1 month in the United States.27 The ASSIP
intervention can be recommended for patients discharged from psychiatric or general hospital care,
given the fact that themonths after hospital discharge are associatedwith a particularly high suicide
risk.28 Because the programmanual is brief and easy to understand for the service users, the
potential dropout rate in clinical practice is expected to be low.
Figure 1. Cost-effectiveness Plane for 24-Month Results for the Number of Suicide Attempts
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Figure 2. Cost-effectiveness Acceptability Curve
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Transferability of Findings
This study was conducted in Switzerland, a country with a relatively high-quality medical care
system. Psychiatric care for suicidal patients is provided as a consultation service to medical
emergency departments and as inpatient and outpatient treatment in psychiatric institutions. In
addition, Switzerland has a high number of psychiatrists in private practice, offering psychiatric and
psychotherapeutic treatment. The funding of health care institutions is partly provided by the state
and partly by the mandatory sickness insurance. Although Switzerland does not have a national
health care system, the provision of care to suicidal patients is generally comparable to most other
Western countries. An earlier study from Switzerland9 reported average costs of €16 700 for
psychiatric inpatient treatment for attempted suicide, while in Australia,13 hospital costs between
A$3015 and A$8534were reported. The same authors suggested that by reducing the suicide
repetition rate from 16% to 13% in Australia, cost savings of A$3041 166 could be achieved.
Considering that the ASSIP trial found a reduction from 27% to 8% in patients reattempting suicide
within 24months, the potential savings in national health care expenditures could be substantial.
Length of psychiatric inpatient care after attempted suicide can vary between institutions and
health care systems. In our study, the average length of psychiatric inpatient care was 21 days for the
ASSIP group and 60 days for the control group. There is a lack of internationally comparable data on
the length of hospitalizations for suicidal patients. A US analysis reported amean length of stay in the
emergency department of 5 days.29 More studies are needed to confirm generalizability issues
between countries and to improve comparability at an international level.
However, with themajority of worldwide suicides occurring in low- andmiddle-income
countries,1 there is an urgent need for replication studies in different national and sociocultural
settings. This would require dissemination of ASSIP to different cultural settings and health
care systems.
Strengths
To our knowledge, our study is the first cost-effectiveness analysis for suicide attempt prevention
alongside an RCT in Switzerland, although there have been a few studies for economic evaluations of
general self-harm prevention. Given the scarcity of economic evidence on effective attempted
suicide prevention strategies in the world, our study will contribute to filling the research gap in the
field and help relevant stakeholders, including funders, commissioners, and health care
professionals, to make rational resource allocation decisions.
The ASSIP intervention is brief, simple, and potentially a cost-saving program. In the base case
analysis, ASSIP was the dominant strategy. The results were robust in a series of sensitivity analyses.
The intervention is relatively easy to learn, and the training curriculum, including case supervision,
amounts to a total of 4 to 5 days per therapist trained. Therapists using ASSIP are expected to have a
background of basic psychotherapy training and practical experience in dealingwith suicidal patients.
Implementation of effective treatments in some countries may not be feasible owing to treatment
costs and the lack of availability of trained health professionals.30 To help build capacity, a train-the-
trainer schema is under development.
The integration of ASSIP into regional and national health care would depend on various health
system infrastructures. For instance, in Switzerland, psychiatric outpatient treatment is readily
available and covered by themandatory insurance system, while in many other health care systems,
those who attempt suicide can only be given minimal follow-up treatments or none at all. In Bern,
the special ASSIP clinic was part of the university psychiatric service, where it was feasible to provide
ASSIP as an add-on treatment to inpatients or outpatients alongside the patient care pathway,
leading to earlier discharge from inpatient care.
Limitations
No officially recommended willingness-to-pay levels exist in terms of cost per self-harm event
averted. Therefore, we recommend that future studies explore further economic impacts using
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generic outcomemeasures, such as data on quality of life. Cost-utility analyses would facilitate
international comparisons andmight help decisionmakers to optimize resource allocation. In
addition, if a broader societal perspective was adopted, including impacts on productivity gained
through effective intervention, the potential for the cost savings would be even greater. Given a
significant association found between deliberate self-harm and violent crime,31 the potential benefits
and cost-savings would be even greater if we take a broader perspective beyond the health sector.
Conclusions
This study found ASSIP to be cost saving in reducing the number of suicide attempts in the study
population. The results suggest that ASSIP can be considered for scale-up in various local and
national settings. Health care professionals will be interested in replicating studies in different
regional and national health care systems. In the future, more economic evaluation studies with
larger sample sizes might be useful to help determine the cost-effectiveness of ASSIP in different
settings at an international level. However, it should be noted that treatments for attempted suicide
and the related costs depend on the local, regional, and national mental health care systems and
cultural contexts.
ARTICLE INFORMATION
Accepted for Publication: August 21, 2018.
Published:October 19, 2018. doi:10.1001/jamanetworkopen.2018.3680
OpenAccess: This is an open access article distributed under the terms of the CC-BY License. © 2018 Park A-L et al.
JAMA Network Open.
Corresponding Author: A-La Park, MSc, Personal Social Services Research Unit, Department of Health Policy,
London School of Economics and Political Science, LondonWC2A 2AE, United Kingdom (a.park@lse.ac.uk).
Author Affiliations: Personal Social Services Research Unit, Department of Health Policy, London School of
Economics and Political Science, London, United Kingdom (Park); Translational Research Centre, University
Hospital of Psychiatry, University of Bern, Bern, Switzerland (Gysin-Maillart, Müller, Michel); Private Clinic
Meiringen, Meiringen, Switzerland (Müller); Department of EmergencyMedicine, University Hospital and
University of Bern, Bern, Switzerland (Exadaktylos).
Author Contributions:Ms Park and Dr Michel had full access to all of the data in the study and take responsibility
for the integrity of the data and the accuracy of the data analysis.
Concept and design: Park, Gysin-Maillart, Exadaktylos, Michel.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Park, Gysin-Maillart, Exadaktylos, Michel.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Park, Gysin-Maillart, Müller, Michel.
Administrative, technical, or material support: Park, Gysin-Maillart, Exadaktylos, Michel.
Supervision: Park, Müller, Exadaktylos, Michel.
Conflict of Interest Disclosures:Drs Gysin-Maillart andMichel received royalties fromHogrefe Publishing for
ASSIP—Attempted Suicide Short Intervention Program: AManual for Clinicians. No other disclosures were reported.
Data Sharing Statement: See Supplement 3.
Additional Contributions:David McDaid, MSc, at the London School of Economics and Political Science reviewed
our final manuscript. Werner Strik, MD, and Franz Moggi, PhD, from the University Hospital of Psychiatry, Bern,
made it possible to carry out this study without external funding. The financial staff at the general hospital, Bern,
provided data and expertise. Contributors did not receive any financial compensation for their assistance.
REFERENCES
1. Fleischmann A, De Leo D. TheWorld Health Organization’s report on suicide: a fundamental step in worldwide
suicide prevention. Crisis. 2014;35(5):289-291. doi:10.1027/0227-5910/a000293
JAMANetworkOpen | Psychiatry Cost-effectiveness of an Intervention Program to Prevent Repeat Suicide Attempts
JAMA Network Open. 2018;1(6):e183680. doi:10.1001/jamanetworkopen.2018.3680 October 19, 2018 9/11
Downloaded From:  by a University of Bern User  on 10/30/2018
2. Carroll R, Metcalfe C, Gunnell D. Hospital presenting self-harm and risk of fatal and non-fatal repetition:
systematic review andmeta-analysis. PLoS One. 2014;9(2):e89944. doi:10.1371/journal.pone.0089944
3. Piscopo K, Lipari RN, Cooney JGC. Suicidal thoughts and behavior among adults: results from the 2015 National
Survey on Drug Use andHealth.NSDUHData Review. 2016. http://www.samhsa.gov/data/. Accessed April 20, 2018.
4. Owens D, Horrocks J, House A. Fatal and non-fatal repetition of self-harm: systematic review. Br J Psychiatry.
2002;181(3):193-199. doi:10.1192/bjp.181.3.193
5. Hawton K, Zahl D, Weatherall R. Suicide following deliberate self-harm: long-term follow-up of patients who
presented to a general hospital. Br J Psychiatry. 2003;182(6):537-542. doi:10.1192/bjp.182.6.537
6. Shepard DS, Gurewich D, Lwin AK, Reed GA Jr, SilvermanMM. Suicide and suicidal attempts in the United
States: costs and policy implications. Suicide Life Threat Behav. 2016;46(3):352-362. doi:10.1111/sltb.12225
7. Platt S, McLean J, McCollam A, et al. Evaluation of the First Phase of Choose Life: The National Strategy and
Action Plan to Prevent Suicide in Scotland. Edinburgh, Scotland: Scottish Executive Social Research; 2006.
8. Tsiachristas A, McDaid D, Casey D, et al. General hospital costs in England of medical and psychiatric care for
patients who self-harm: a retrospective analysis. Lancet Psychiatry. 2017;4(10):759-767. doi:10.1016/S2215-0366
(17)30367-X
9. Czernin S, Vogel M, Flückiger M, et al. Cost of attempted suicide: a retrospective study of extent and associated
factors. Swiss MedWkly. 2012;142:w13648.
10. Hawton K, Witt KG, Salisbury TLT, et al. Psychosocial interventions following self-harm in adults: a systematic
review andmeta-analysis. Lancet Psychiatry. 2016;3(8):740-750. doi:10.1016/S2215-0366(16)30070-0
11. Zalsman G, Hawton K, Wasserman D, et al. Suicide prevention strategies revisited: 10-year systematic review.
Lancet Psychiatry. 2016;3(7):646-659. doi:10.1016/S2215-0366(16)30030-X
12. Inagaki M, Kawashima Y, Kawanishi C, et al. Interventions to prevent repeat suicidal behavior in patients
admitted to an emergency department for a suicide attempt: a meta-analysis. J Affect Disord. 2015;175:66-78. doi:
10.1016/j.jad.2014.12.048
13. Hetrick SE, Robinson J, Spittal MJ, Carter G. Effective psychological and psychosocial approaches to reduce
repetition of self-harm: a systematic review, meta-analysis andmeta-regression. BMJ Open. 2016;6(9):e011024.
doi:10.1136/bmjopen-2016-011024
14. Bustamante Madsen L, EddlestonM, Schultz Hansen K, Konradsen F. Quality assessment of economic
evaluations of suicide and self-harm interventions. Crisis. 2018;39(2):82-95. doi:10.1027/0227-5910/a000476
15. Gysin-Maillart A, Schwab S, Soravia L, Megert M, Michel K. A novel brief therapy for patients who attempt
suicide: a 24-months follow-up randomized controlled study of the Attempted Suicide Short Intervention Program
(ASSIP). PLoS Med. 2016;13(3):e1001968. doi:10.1371/journal.pmed.1001968
16. Husereau D, DrummondM, Petrou S, et al; CHEERS Task Force. Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) statement. Clin Ther. 2013;35(4):356-363. doi:10.1016/j.clinthera.2013.03.003
17. SilvermanMM, Berman AL, Sanddal ND, O’Carroll PW, Joiner TE. Rebuilding the tower of Babel: a revised
nomenclature for the study of suicide and suicidal behaviors, part 1: background, rationale, andmethodology.
Suicide Life Threat Behav. 2007;37(3):248-263. doi:10.1521/suli.2007.37.3.248
18. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions
and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization; 2014.
19. RickhamPP. Human Experimentation: Code of Ethics of theWorldMedical Association: Declaration of Helsinki.
BMJ. 1964;2(5402):177. doi:10.1136/bmj.2.5402.177
20. Michel K, Gysin-Maillart A. ASSIP—Attempted Suicide Short Intervention Program: AManual for Clinicians.
Göttingen, Germany: Hogrefe Publishing; 2015. doi:10.1027/00476-000
21. Bieleninik L, Geretsegger M, Mössler K, et al; TIME-A Study Team. Effects of improvisational music therapy vs
enhanced standard care on symptom severity among children with autism spectrum disorder: the TIME-A
randomized clinical trial. JAMA. 2017;318(6):525-535. doi:10.1001/jama.2017.9478
22. Efron B. Better bootstrap confidence intervals. J Am Stat Assoc. 1987;82(397):171-185. doi:10.1080/01621459.
1987.10478410
23. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. Oxford, UK: Oxford University
Press; 2014. doi:10.1093/med/9780199685028.001.0001
24. Blank PR, Ademi Z, Lu X, Szucs TD, SchwenkglenksM. Herpes zoster vaccine: A health economic evaluation for
Switzerland.Hum Vaccin Immunother. 2017;13(7):1495-1504. doi:10.1080/21645515.2017.1308987
JAMANetworkOpen | Psychiatry Cost-effectiveness of an Intervention Program to Prevent Repeat Suicide Attempts
JAMA Network Open. 2018;1(6):e183680. doi:10.1001/jamanetworkopen.2018.3680 October 19, 2018 10/11
Downloaded From:  by a University of Bern User  on 10/30/2018
25. European Network for Health Technology Assessment.Methods for Health Economic Evaluations, a Guideline
Based on Current Practices in Europe. Diemen, Netherlands: European Network for Health Technology
Assessment; 2015.
26. National Institute for Health and Care Excellence.Methods for the Development of NICE Public Health
Guidance. London, UK: National Institute for Health and Care Excellence; 2012.
27. OlfsonM, Marcus SC, Bridge JA. Emergency treatment of deliberate self-harm. Arch Gen Psychiatry. 2012;69
(1):80-88. doi:10.1001/archgenpsychiatry.2011.108
28. Morthorst B, Krogh J, Erlangsen A, Alberdi F, Nordentoft M. Effect of assertive outreach after suicide attempt
in the AID (assertive intervention for deliberate self harm) trial: randomised controlled trial. BMJ. 2012;345:e4972.
doi:10.1136/bmj.e4972
29. Owens PL, Fingar KR, Heslin K, Mutter R, Booth CL. Emergency Department Visits Related to Suicidal Ideation,
2006–2013. Rockville, MD: Agency for Healthcare Research and Quality; 2017.
30. Fleischmann A, Arensman E, Berman A, et al. Overview evidence on interventions for population suicide with
an eye to identifying best-supported strategies for LMICs. Glob Ment Health (Camb). 2016;3:e5. doi:10.1017/gmh.
2015.27
31. Sahlin H, Kuja-Halkola R, Bjureberg J, et al. Association between deliberate self-harm and violent criminality.
JAMA Psychiatry. 2017;74(6):615-621. doi:10.1001/jamapsychiatry.2017.0338
SUPPLEMENT 1.
Trial Protocol
SUPPLEMENT 2.
eTable 1.Unit Costs
eTable 2. Breakdown of Total Training Costs for the ASSIP
SUPPLEMENT 3.
Data Sharing Statement
JAMANetworkOpen | Psychiatry Cost-effectiveness of an Intervention Program to Prevent Repeat Suicide Attempts
JAMA Network Open. 2018;1(6):e183680. doi:10.1001/jamanetworkopen.2018.3680 October 19, 2018 11/11
Downloaded From:  by a University of Bern User  on 10/30/2018
